Keuttner K, Godberg VM, (Eds): Osteoarthritic Disorders. 1995, Rosemont, IL, USA: American Academy of Orthopaedic Surgeons, 21-25.
Google Scholar
Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM: Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum. 1995, 38: 1134-1141. 10.1002/art.1780380817.
Article
CAS
PubMed
Google Scholar
Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002, 295: 2387-2392. 10.1126/science.1067100.
Article
CAS
PubMed
Google Scholar
Chau I, Rigg A, Cunningham D: Matrix metalloproteinase inhibitors – an emphasis on gastrointestinal malignancies. Crit Rev Oncol Hematol. 2003, 45: 151-176. 10.1016/S1040-8428(02)00015-X.
Article
PubMed
Google Scholar
Shaw T, Nixon JS, Bottomley KM: Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Expert Opin Investig Drugs. 2000, 9: 1469-1478. 10.1517/13543784.9.7.1469.
Article
CAS
PubMed
Google Scholar
Bigg HF, Rowan AD: The inhibition of metalloproteinases as a therapeutic target in rheumatoid arthritis and osteoarthritis. Curr Opin Pharmacol. 2001, 1: 314-320. 10.1016/S1471-4892(01)00055-8.
Article
CAS
PubMed
Google Scholar
Cawston TE: Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther. 1996, 70: 163-182. 10.1016/0163-7258(96)00015-0.
Article
CAS
PubMed
Google Scholar
Lohmander LS, Hoerrner LA, Lark MW: Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum. 1993, 36: 181-189. 10.1002/art.1780360906.
Article
CAS
PubMed
Google Scholar
Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead NG, De B, et al: Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage. 2001, 9: 751-760. 10.1053/joca.2001.0472.
Article
CAS
PubMed
Google Scholar
Fujisawa T, Igeta K, Odake S, Morita Y, Yasuda J, Morikawa T: Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model. Bioorg Med Chem. 2002, 10: 2569-2581. 10.1016/S0968-0896(02)00109-8.
Article
CAS
PubMed
Google Scholar
Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, Brown PA, Budd JM, Elliott L, Greenham AK, et al: Ro 32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol. 1997, 121: 540-546. 10.1038/sj.bjp.0701150.
Article
PubMed Central
CAS
PubMed
Google Scholar
Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KM: Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum. 1998, 41: 1639-1644. 10.1002/1529-0131(199809)41:9<1639::AID-ART15>3.0.CO;2-0.
Article
CAS
PubMed
Google Scholar
Close DR: Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis. 2001, 60 (Suppl 3): iii62-67.
PubMed Central
CAS
PubMed
Google Scholar
Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L: A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006, 102: 300-308. 10.1016/j.ygyno.2005.12.020.
Article
CAS
PubMed
Google Scholar
Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, et al: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998, 4: 1101-1109.
CAS
PubMed
Google Scholar
Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997, 75: 69-75. 10.1016/S0163-7258(97)00023-5.
Article
CAS
PubMed
Google Scholar
Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, et al: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002, 86: 1864-1870. 10.1038/sj.bjc.6600310.
Article
PubMed Central
CAS
PubMed
Google Scholar
Tierney GM, Griffin NR, Stuart RC, Kasem H, Lynch KP, Lury JT, Brown PD, Millar AW, Steele RJ, Parsons SL: A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer. 1999, 35: 563-568. 10.1016/S0959-8049(99)00007-6.
Article
CAS
PubMed
Google Scholar
Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002, 20: 1383-1388. 10.1200/JCO.20.5.1383.
Article
CAS
PubMed
Google Scholar
Rosemurgy A, Harris J, Langleben A, Casper E, Goode S, Rasmussen H: Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol. 1999, 22: 247-252. 10.1097/00000421-199906000-00007.
Article
CAS
PubMed
Google Scholar
Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodi TA, et al: Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998, 16: 2150-2156.
CAS
PubMed
Google Scholar
Hutchinson JW, Tierney GM, Parsons SL, Davis TR: Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br. 1998, 80: 907-908. 10.1302/0301-620X.80B5.8464.
Article
CAS
PubMed
Google Scholar
Brown PD: Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Invest Drugs. 2000, 9: 2167-2177. 10.1517/13543784.9.9.2167.
Article
CAS
Google Scholar
Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P, Gillet P: Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997, 40: 1670-1679. 10.1002/art.1780400917.
Article
CAS
PubMed
Google Scholar
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, et al: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connective tissue disease due to inadequate collagen turnover. Cell. 1999, 99: 81-92. 10.1016/S0092-8674(00)80064-1.
Article
CAS
PubMed
Google Scholar
Buckland-Wright JC, Macfarlane DG, Williams SA, Ward RJ: Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis. 1995, 54: 872-880.
Article
PubMed Central
CAS
PubMed
Google Scholar
Buckland-Wright JC, Macfarlane DG, Lynch JA, Jasani MK: Quantitative microfocal radiography detects changes in OA knee joint space width in subjects in placebo-controlled trial of NSAID therapy. J Rheumatol. 1995, 22: 937-943.
CAS
PubMed
Google Scholar
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al: Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986, 29: 1039-1049. 10.1002/art.1780290816.
Article
CAS
PubMed
Google Scholar
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW: Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988, 15: 1833-1840.
CAS
PubMed
Google Scholar
Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975, 31: 103-115. 10.2307/2529712.
Article
CAS
PubMed
Google Scholar
Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, et al: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006, 354: 795-808. 10.1056/NEJMoa052771.
Article
CAS
PubMed
Google Scholar
Ernst E: Glucosamine and chondroitin sulfate for knee osteoarthritis. N Engl J Med. 2006, 354: 2184-2185. 10.1056/NEJMc060829.
Article
CAS
PubMed
Google Scholar
Altman RD, Moskowitz R: Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol. 1998, 25: 2203-2212.
CAS
PubMed
Google Scholar
Lehmann R, Brzosko M, Kopsa P, Nischik R, Kresisse A, Thurston H, Litschig S, Sloan VS: Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin. 2005, 21: 517-526. 10.1185/030079905X38196.
Article
CAS
PubMed
Google Scholar
Wojtowicz-Praga S: Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999, 1: 117-129. 10.2165/00126839-199901020-00001.
Article
CAS
PubMed
Google Scholar
Sher JS, Uribe JW, Posada A: Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg. 1995, 77A: 10-15.
Google Scholar
Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicoloson M, Mercier R, Mazabel E, Penning C, Zhang MH, et al: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol. 2005, 23: 842-849. 10.1200/JCO.2005.03.170.
Article
CAS
PubMed
Google Scholar